ISRGMEDIUM SIGNALFINANCIAL10-K

Intuitive Surgical delivered strong financial performance with 20.5% revenue growth and significant cash accumulation, while expanding regulatory risk disclosures and reducing share count.

The company demonstrates robust operational execution with revenue reaching $10.1B and operating margins remaining strong despite growth investments. However, expanded regulatory language around FDA compliance, trade policy risks, and data privacy regulations suggests management is preparing for a more complex operating environment that could impact future growth trajectories.

Comparing 2026-02-03 vs 2025-01-31View on EDGAR →
FINANCIAL ANALYSIS

ISRG posted impressive across-the-board growth with revenue up 20.5% to $10.1B, operating income rising 25.4% to $2.9B, and cash surging 66% to $3.4B, indicating strong cash generation and conservative capital allocation. The company expanded working capital with accounts receivable and inventory growing roughly in line with revenue growth, while current liabilities increased at a more modest pace. The overall financial picture signals a company in strong operational health with substantial liquidity and growing market demand for its robotic surgical systems.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+66.1%
$2.0B→$3.4B

Cash position surged 66.1% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+37.5%
$7.1B→$9.8B

Current assets grew 37.5% — improving short-term liquidity or inventory/receivables build.

Operating Cash Flow
Cash Flow
+25.5%
$2.4B→$3.0B

Operating cash flow grew 25.5% — strong conversion of earnings to cash, healthy business fundamentals.

Operating Income
P&L
+25.4%
$2.3B→$2.9B

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Accounts Receivable
Balance Sheet
+24.6%
$1.2B→$1.5B

Receivables grew 24.6% — monitor days sales outstanding for collection efficiency.

Inventory
Balance Sheet
+23.7%
$1.5B→$1.8B

Inventory built 23.7% — monitor whether demand supports this build or if write-downs may follow.

Net Income
P&L
+23%
$2.3B→$2.9B

Net income grew 23% — bottom-line growth signals improving overall business health.

Revenue
P&L
+20.5%
$8.4B→$10.1B

Revenue growing 20.5% — solid top-line momentum, watch margins for quality of growth.

Gross Profit
P&L
+17.9%
$5.6B→$6.6B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Current Liabilities
Balance Sheet
+14.9%
$1.7B→$2.0B

Current liabilities rose 14.9% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-02-03
PRIOR — 2025-01-31
ADDED
The number of outstanding shares of the registrant s common stock as of January 28, 2026, was 355,130,237 .
Statements using words such as estimates, projects, believes, anticipates, plans, expects, intends, may, will, could, commit, ensure, promote, should, would, goals, seek, potential, targeted, and similar words and expressions are intended to identify forward-looking statements.
Food and Drug Administration ( FDA ), comparable regulatory authorities, or notified bodies; the risk of our inability to comply with complex FDA and other regulations, which may result in significant enforcement actions; regulatory approvals, clearances, certifications, and restrictions or any dispute that may occur with any regulatory body; healthcare reform legislation in the U.S.
on imports from various countries, including Mexico, where we currently manufacture a significant majority of our instruments and accessories, Germany, where we currently manufacture a majority of our endoscopes, and China, where we currently import certain materials); and other risks and uncertainties, including those listed under the caption Risk Factors.
We are subject to litigation, investigations, and other legal proceedings relating to our products, customers, competitors, and government regulators that may adversely affect our business, financial condition, or results of operations.
+7 more — sign up free →
REMOVED
The number of outstanding shares of the registrant s common stock as of January 27, 2025, was 356,656,964 .
Statements using words such as estimates, projects, believes, anticipates, plans, expects, intends, may, will, could, should, would, targeted, and similar words and expressions are intended to identify forward-looking statements.
presidential administration on imports from Mexico, where we currently manufacture a significant majority of our instruments and accessories); and other risks and uncertainties, including those listed under the caption Risk Factors.
We are subject to litigation, investigations, and other legal proceedings relating to our products, customers, competitors, and government regulators that could materially adversely affect our financial condition, divert management s attention, and harm our business.
Our business is subject to complex and evolving laws and regulations regarding data privacy, data protection, artificial intelligence, and responsible use of data.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →